Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 31, 2017
Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced today that they have extended their drug discovery collaboration...
-
May 30, 2017
Eisai Inc., the U.S. subsidiary of Tokyo, Japan-based Eisai Co., Ltd., announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research...
-
May 18, 2017- Full results of Study 304, a Phase 3 study evaluating the safety and efficacy of Lenvima® (lenvatinib) as compared to sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma, to be presented in an oral presentation on Sunday, June 4 at 8:12 a.m. CDT
Eisai Inc. announced today the presentation of new data and analyses at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – 7 in Chicago. The data to be presented...
-
Apr 27, 2017Data to be Presented at the American Academy of Neurology "Best Of" Epilepsy Session
Eisai Inc. announced today the presentation of results from a new meta-analysis of published clinical trials showing that the effect of adjunctive antiepileptic drug (AED) treatment versus placebo...
-
Apr 19, 20175-YEAR ANNIVERSARY OF LONDON DECLARATION ON NEGLECTED TROPICAL DISEASES
Eisai Inc. announced today that its parent company Tokyo, Japan-based Eisai Co., Ltd. has pledged the continuing support of its initiatives for the elimination of lymphatic filariasis (LF), a...